impress clinic response observe use chime antigen receptor car cell target cd hematolog align limit benefit variety solid tumor result studi highlight sever obstacle face context include insuffici home tumor site lack expand persist count highly immunosuppress microenviron heterogen express review outcome discus strategy improv antitumor active 